The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.

The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.

Previous work has shown an association between the K variant of the butyrylcholinesterase (BCHE) gene and Alzheimer's disease (AD) in patients carrying the epsilon4 allele of ApoE. We attempted to replicate this finding in 181 UK white AD cases and 71 controls. No difference was found in BCHE-K...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Kehoe, P, Williams, H, Holmans, P, Wilcock, G, Cairns, N, Neal, J, Owen, M
Formato:	Journal article
Idioma:	English
Publicado em:	1998

Registros relacionados

Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease.
por: Kehoe, P, et al.
Publicado em: (1999)

Association between a PS-1 intronic polymorphism and late onset Alzheimer's disease.
por: Kehoe, P, et al.
Publicado em: (1996)

Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
por: Roger M. Lane, et al.
Publicado em: (2024-04-01)

Presenilin-1 polymorphism and Alzheimer's disease. The UK Alzheimer's Disease Collaborative Group.
por: Kehoe, P, et al.
Publicado em: (1996)

Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease.
por: Lehmann, D, et al.
Publicado em: (2000)

Presenilin-1 polymorphism and Alzheimer's disease [6]
por: Kehoe, P, et al.
Publicado em: (1996)

Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.
por: Holmes, C, et al.
Publicado em: (2005)

Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease.
por: Kehoe, P, et al.
Publicado em: (2004)

ApoE epsilon 2 and butyrylcholinesterase K variant are associated with coronary heart disease in type 2 diabetes
por: Horton, V, et al.
Publicado em: (2000)

Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain.
por: Blomqvist, M, et al.
Publicado em: (2005)

Butyrylcholinesterase K variant is associated with type 2 diabetes in UK Caucasians
por: Hashim, Y, et al.
Publicado em: (2000)

Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients
por: Pongthanaracht N, et al.
Publicado em: (2017-05-01)

Flavonoids as Inhibitors of Human Butyrylcholinesterase Variants
por: Maja Katalinić, et al.
Publicado em: (2014-01-01)

Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?
por: Kehoe, P, et al.
Publicado em: (2007)

Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients.
por: Tasker, A, et al.
Publicado em: (2008)

Common variants of ACE contribute to variable age at onset of Alzheimer's disease
por: Katzov, H, et al.
Publicado em: (2004)

Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism.
por: Katzov, H, et al.
Publicado em: (2004)

The renin angiotensin system in Alzheimer's disease - Do updates high-light a clinical and biological dichotomy?
por: Kehoe, P, et al.
Publicado em: (2006)

Obesity and variants of the GHRL (ghrelin) and BCHE (butyrylcholinesterase) genes
por: Vitor G.L. Dantas, et al.
Publicado em: (2011-01-01)

Kinetics and computational study of butyrylcholinesterase inhibition by methylrosmarinate: relevance to Alzheimer’s disease treatment
por: Sani Muhammad Uzairu, et al.
Publicado em: (2022-09-01)

Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.
por: Hashim, Y, et al.
Publicado em: (2001)

Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease.
por: Culpan, D, et al.
Publicado em: (2003)

Benzene-1,3-diol derivatives as the inhibitors of butyrylcholinesterase: An emergent target of Alzheimer’s disease
por: Dongliang Yin, et al.
Publicado em: (2022-01-01)

Aaptamine – a dual acetyl – and butyrylcholinesterase inhibitor as potential anti-Alzheimer’s disease agent
por: Shuang Miao, et al.
Publicado em: (2022-12-01)

Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer’s Disease—Could <i>BCHE</i> Genotyping Be Helpful in Alzheimer’s Therapy?
por: Jacek Jasiecki, et al.
Publicado em: (2019-10-01)

TNFR-associated factor-2 (TRAF-2) expression in Alzheimer's disease
por: Culpan, D, et al.
Publicado em: (2004)

The relationship between CAV-1 and cerebral amyloid angiopathy in Alzheimer's disease
por: Chalmers, K, et al.
Publicado em: (2004)

Widely Spread Butyrylcholinesterase Can Hydrolyze Acetylcholine in the Normal and Alzheimer Brain
por: Marsel Mesulam, et al.
Publicado em: (2002-02-01)

Haplotypes extending across ACE are associated with Alzheimer's disease.
por: Kehoe, P, et al.
Publicado em: (2003)

Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer’s disease
por: Chuanyu Yu, et al.
Publicado em: (2024-12-01)

Design, Synthesis and Biological Evaluation of Biscarbamates as Potential Selective Butyrylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease
por: Ana Matošević, et al.
Publicado em: (2022-09-01)

Investigation of Association between Susceptibility to Leprosy and SNPs inside and near the BCHE Gene of Butyrylcholinesterase
por: Henrique J. P. Gomes, et al.
Publicado em: (2012-01-01)

The ACE gene and Alzheimer's disease susceptibility.
por: Narain, Y, et al.
Publicado em: (2000)

Biophenols of mints: Antioxidant, acetylcholinesterase, butyrylcholinesterase and histone deacetylase inhibition activities targeting Alzheimer’s disease treatment
por: Doaa M. Hanafy, et al.
Publicado em: (2017-06-01)

Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors Based on the Pyridyl–Pyridazine Moiety for the Potential Treatment of Alzheimer’s Disease
por: Mohamed Elsawalhy, et al.
Publicado em: (2024-10-01)

Correction: Evolution of Acetylcholinesterase and Butyrylcholinesterase in the Vertebrates: An Atypical Butyrylcholinesterase from the Medaka.
por: Leo Pezzementi, et al.
Publicado em: (2011-01-01)

Treating Alzheimer's disease.
por: Wilcock, G, et al.
Publicado em: (1995)

Evolution of acetylcholinesterase and butyrylcholinesterase in the vertebrates: an atypical butyrylcholinesterase from the Medaka Oryzias latipes.
por: Leo Pezzementi, et al.
Publicado em: (2011-02-01)

Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.
por: Miners, J, et al.
Publicado em: (2006)

Protein and gene expression of tumour necrosis factor receptors I and II and their promoter gene polymorphisms in Alzheimer's disease.
por: Culpan, D, et al.
Publicado em: (2007)